illumicell AI Raises $2M to Transform Semen Diagnostics with AI
Summary
What You Should Know: Techmed startup illumicell AI, founded by a team of Harvard-trained physician Michel Bielecki, former McKinsey consultant Jeyla Sadikova, and rocket engineer Loup Cordey, has secured $2M in pre-seed funding. In the U.S., a large number of sperm tests are referred by doctors and specialists, but only a limited number of clinics can process them, leading to delays for patients.illumicell AIs technology, which includes a proprietary, portable imaging system and AI-driven algorithms, aims to resolve these bottlenecks by providing results 50 times faster and at 20 times lower cost, directly in any doctors office.Dr. Michel Bielecki, co-founder and CEO of illumicell AI, emphasizes the potential to improve healthcare quality by enabling real-time, lab-grade fluid diagnostics in any doctors office, reducing wait times and costs for patients. The company is building a real-time dataset in male reproductive health, currently comprising over 400,000 data points.This data has the potential to provide personalized fertility insights, including:While initially focused on fertility, illumicell AIs platform has the potential to be applied to other bodily fluids, enabling real-time cellular intelligence across various healthcare fields.illumicell AI reports that its prototype has shown strong correlation to gold-standard lab results in clinical trials, outperforming legacy systems. The company has secured Letters of Intent (LOIs) with fertility clinics in the USA, Japan, and Switzerland, and plans to submit for FDA approval in 2026. illumicell AI has also received recognition from innovation programs such as Harvard Innovation Labs, Creative Destruction Lab, MassChallenge Boston, Techstars, and Keihanna KGAP+ in Japan, and was acknowledged by the American Urological Association.Fertility remains rooted in traditional approaches still placing the burden of fertility almost entirely on women.